Is the PRESENT study a present for people with breast cancer?

flowerIs the PRESENT study a present for people with breast cancer?

A small biopharmaceutical company (Galena Biopharma) passed a major milestone today in gaining the 70th qualifying disease free survival patient in a phase three FDA study. What this means is that an interim analysis (early look at results) will be undertaken.

The benefit for potentially millions of breast cancer patients is that they can receive a vaccine (NeuVax) if the experimental vaccine reaches FDA approval.

More to follow as usual but the promise of PRESENT can’t be underestimated.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.